AstraZeneca launches new HealthTech business to spawn nextgen medicines
Cambridge-headquartered Big Biotech AstraZeneca has launched a global health-tech business, Evinova, to accelerate innovation across the life sciences sector.
Evinova was launched today within AstraZeneca to bring to market digital health solutions that are science-based, evidence-led, and human experience-driven. AZ will combine its deep scientific experience with its digital and AI expertise to serve the wider healthcare community and create new standards for the sector.
Drawing on AstraZeneca’s experience of developing novel therapeutics and with insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech and clinical research organisations (CROs) to support clinical research globally.
Digital transformation is happening at pace within the healthcare industry. AstraZeneca has made strategic investments and significant advances in this space in recent years. This includes developing innovative digital solutions to improve the patient experience in clinical trials and accelerate getting new medicines to patients.
Evinova will prioritise bringing to market scaled digital technology solutions already being used by AstraZeneca in 40 countries globally to optimise clinical trial design and delivery.
This will seek to reduce the time and cost of developing new medicines, bring care closer to home for patients and reduce the burden on health systems. Evinova will also pursue opportunities in digital remote patient monitoring and digital therapeutics with a pipeline of digital innovations in these areas.
Globally-leading CROs Parexel and Fortrea have entered into agreements to offer Evinova digital health solutions to their wide customer base. To accelerate industry adoption and sustain and expand the global reach of its products, Evinova is collaborating with Accenture and Amazon Web Services.
Pascal Soriot, Chief Executive Officer, AstraZeneca said: “The future of medicine development can be accelerated with digital solutions. We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.”
Cristina Durán, President of Evinova, added: “We are excited to bring the portfolio of globally-scaled digital solutions developed to serve AstraZeneca’s drug development pipeline to the wider life sciences community. We believe this will help propel the sector forward in digital health as we know healthcare professionals and regulators need digital solutions that work across pharma companies and support patients broadly.
“Coming from within the sector and with proven experience, Evinova is well placed to deliver evidence-led, science-based and human experience-driven solutions with the aim of improving patient experience and outcomes.”